Edesa Biotech shares are trading lower after the company published data from a Phase 2 substudy of its ARDS candidate.
Portfolio Pulse from Benzinga Newsdesk
Edesa Biotech has published data from a Phase 2 substudy of its ARDS candidate, which has led to a decrease in its share price.
September 28, 2023 | 2:31 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Edesa Biotech's stock price is trading lower after the company published data from a Phase 2 substudy of its ARDS candidate.
The release of the Phase 2 substudy data for Edesa Biotech's ARDS candidate has negatively impacted the company's stock price. This suggests that the market may have had higher expectations for the results of the study.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100